Humanin Research: Mitochondria-Derived Peptide and Neuroprotection
Humanin is a 21 amino acid mitochondria-derived peptide encoded in the MT-RNR2 locus, discovered through screening for factors protecting against Alzheimer disease-related neuronal toxicity. This guide covers receptor pharmacology, neuroprotection mechanisms, and metabolic research applications.
Humanin Research: Mitochondria-Derived Peptide and Neuroprotection
Humanin is a 21 amino acid peptide encoded within the mitochondrial 16S ribosomal RNA gene (MT-RNR2) in an alternative open reading frame. Its discovery by Hashimoto et al. in 2001 (PNAS) through expression cloning screening for factors protecting neuronal cells from mutant amyloid precursor protein toxicity established the first known mitochondria-encoded cytoprotective peptide and launched the field of mitochondria-derived peptides (MDPs).
Discovery and the MDP Field
The identification of Humanin from a cDNA library derived from occipital lobe of an Alzheimer disease patient — screening for clones that rescued cortical neurons from APP mutant-induced apoptosis — was unexpected because the protective sequence mapped to the mitochondrial genome rather than the nuclear genome. This discovery challenged the prevailing understanding that the mitochondrial genome encoded only 13 proteins (all components of the oxidative phosphorylation machinery), 22 tRNAs, and 2 rRNAs — with no signalling peptides.
Subsequent research established the MDP family: MOTS-c (encoded in the 12S rRNA gene), six small humanin-like peptides (SHLP1-6) encoded in the 16S rRNA locus alongside Humanin, and potentially additional MDPs still being characterised. These findings established that the mitochondrial genome functions as a source of bioactive signalling peptides — not merely a compact energy metabolism gene cluster — with profound implications for understanding mitochondrial retrograde signalling.
Receptor Systems
CNTFR/WSX-1/gp130 tripartite complex: Humanin activates the same heterotrimeric receptor complex used by ciliary neurotrophic factor (CNTF) and cardiotrophin-1. This complex consists of CNTFR (ligand binding alpha subunit), WSX-1 (IL-27 receptor alpha, signal-transducing subunit), and gp130 (IL-6 receptor signal transducer, shared across the IL-6 family). Receptor activation drives JAK1/JAK2 phosphorylation, followed by STAT3 phosphorylation at Tyr705 (the primary downstream readout for Humanin's receptor-mediated neuroprotective signalling).
IGFBP-3 interaction: Humanin also signals through IGFBP-3 (insulin-like growth factor binding protein 3) and its putative receptor, with published data suggesting a functional interaction between Humanin and the IGF axis. The physiological significance of this interaction relative to the CNTFR complex pathway remains an active research question.
G14 critical residue: Structure-activity relationship research has established that glycine at position 14 (G14) is essential for neuroprotective activity. The G14A substitution (Humanin[G14A]) abolishes neuroprotection while retaining receptor binding, making it a useful negative control tool. Request G14A-Humanin from Signal Labs if studying receptor binding independently of downstream neuroprotective function.
Neuroprotection Research
APP toxicity model: Cortical neurons from embryonic day 18 rat cortex, cultured until DIV14. Treat with conditioned medium from APP-V717F-expressing cells (which contains toxic APP-related fragments) with and without Humanin (1fM-10nM) co-treatment. Measure viability by calcein-AM/ethidium homodimer (live-dead) imaging at 24-48 hours. Include Humanin[G14A] at matched concentrations as negative control to confirm sequence-dependent neuroprotection.
Beta-amyloid toxicity: Prepare Abeta42 oligomers by dissolving peptide in HFIP, drying, reconstituting in DMSO at 5mM, then diluting in F12 medium and incubating at 4°C for 24 hours. Apply Abeta42 oligomers (5µM) to cortical neurons with or without Humanin pre-treatment (1 hour prior, 1nM-1µM). Assess: viability (MTT); caspase-3 activity (fluorogenic substrate); phospho-STAT3 (Western blot, 15 minutes Humanin pre-treatment before readout); and neurite integrity (MAP2 immunofluorescence, automated analysis of neurite length and branching).
Oxidative stress model: H2O2 (100-500µM, 4 hours) applied to SH-SY5Y cells or primary neurons. Humanin pre-treatment (1 hour) at 1pM-100nM. Endpoints: cell viability (trypan blue exclusion, LDH release), ROS measurement (CM-H2DCFDA fluorescence), mitochondrial membrane potential (JC-1), and Bcl-2/Bax ratio by Western blot.
Metabolic Research
Beyond neuroprotection, published research has connected Humanin to metabolic function. In hepatocytes, Humanin activates STAT3 signalling to suppress glucose output — a potential mechanism for hepatic insulin sensitisation. In adipocytes, Humanin has been proposed to modulate adiponectin secretion. Plasma Humanin concentrations decline with age in humans, paralleling the age-related increase in metabolic syndrome prevalence.
Hepatocyte glucose output assay: Primary rat hepatocytes or HepG2 cells stimulated with glucagon (100nM) to activate glycogenolysis and gluconeogenesis. Humanin treatment (1nM-1µM) before or alongside glucagon stimulation. Measure glucose in conditioned medium by glucose oxidase assay at 6 and 24 hours. Confirm STAT3 involvement using the gp130 inhibitor SC144 (10µM).
Key Published Research
- Hashimoto Y, et al. "A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ." PNAS, 2001. PMID: 11717412
- Guo B, et al. "Humanin peptide suppresses apoptosis by interfering with Bax activation." Nature, 2003. PMID: 14576432
- Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 2015. PMID: 25738459
For laboratory and analytical research purposes only. Not for human or veterinary use.